Skip to main content

Advertisement

SpringerLink
Log in

Biologic-Associated Infections in Pediatric Rheumatology

  • Infections and Arthritis (K Winthrop, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

During the past 15 years, biologics for juvenile idiopathic arthritis (JIA) therapy has led to new options. However, despite the high effectiveness and safety profile of these agents, infections are of great concern. The risk for bacterial infections, which appears to be increased in JIA patients as a result of the disease itself, seems to be increased further by antirheumatic treatment. Combining data from several sources, infection rates appear to be comparable for abatacept (1.33/100 person-years (PY); 95 % confidence interval (CI) = 0.50–2.48), adalimumab (1.42/100 PY; 1.01–1.99), and etanercept (1.28/100 PY; 1.06–1.55); higher with golimumab (3.03/100 PY; 1.26–7.29) and infliximab (3.42/100 PY; 1.71–6.84); and even higher with tocilizumab (8.62/100 PY; 6.69–11.10). The rate of serious infection was lowest with methotrexate (0.67/100 PY; 0.48–0.93). In patient cohorts treated with methotrexate without a biologic as a comparator, risk ratios for serious infections were significantly increased for all biologics, except abatacept, because of insignificant patient numbers. Opportunistic infections, including tuberculosis, were very rare. Herpes zoster was the only specific infection occurring frequently throughout the studies. Thus, the safety profiles of approved biologics are highly acceptable. Although this conclusion is based on limited experience and is not easily expanded to the interleukin (IL)-1 inhibitor canakinumab or the T cell activation inhibitor abatacept, both these agents have demonstrated an excellent safety profile so far.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beukelman T, Patkar NM, Saag KG, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465–82.

    Article  Google Scholar 

  2. Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother. 2009;10:3049–60.

    Article  CAS  PubMed  Google Scholar 

  3. Lovell DJ, Giannini EH, Reiff A, et al. For the Pediatric Rheumatology Collaborative Study Group: etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763–9.

    Article  CAS  PubMed  Google Scholar 

  4. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003;62:245–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096–106.

    Article  CAS  PubMed  Google Scholar 

  6. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20.

    Article  CAS  PubMed  Google Scholar 

  7. Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73:1114–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54:1987–94.

    Article  PubMed  Google Scholar 

  9. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496–504.

    Article  CAS  PubMed  Google Scholar 

  10. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69:718–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Horneff G, Schmeling H, Biedermann. The German etanercept registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2004;63:1638–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry. Ann Rheum Dis. 2009;68:519–25.

    Article  CAS  PubMed  Google Scholar 

  13. Horneff G, Foeldvari I, Minden K, et al. 10 years experience in the German JIA etanercept registry—lessons from changing patient populations. Arthritis Rheum. 2011;31:334–42.

    Google Scholar 

  14. Prince FH, Twil M, Ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635–41.

    Article  CAS  PubMed  Google Scholar 

  15. Davies R, Southwood TR, Kearsley-Fleet L, Lunt M, Hyrich KL, British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR ETN). Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis Rheumatol. 2015;67:2487–94. doi:10.1002/art.39197.

    Article  CAS  PubMed  Google Scholar 

  16. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:2794–804.

    Article  CAS  PubMed  Google Scholar 

  17. Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27:651–62.

    Article  CAS  PubMed  Google Scholar 

  18. Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Wouters C, Panaviene V, et al. A multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results of GO-KIDS trial. Arthritis Rheum. 2014;66(Supplement):S414.

    Google Scholar 

  19. Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2012–21.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Wallace CA, Ringold S, Bohnsack J, et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol. 2014;41(12):2459–65.

    Article  PubMed  Google Scholar 

  21. Zuber Z, Rutkowska-Sak L, Postepski J, et al. Etanercept treatment in juvenile idiopathic arthritis: the Polish registry. Med Sci Monit. 2011;17:SR35–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Nimmrich S, Horneff G. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients. Rheumatol Int. 2015;35:465–70.

    Article  CAS  PubMed  Google Scholar 

  23. Horneff G, Fitter S, Foeldvari I, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012;14(5):R230.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Burgos-Vargas R, Tse SML, Horneff G, et al. A randomized, double-blind, placebo-controlled, multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res. 2015. doi:10.1002/acr.22657.

    Google Scholar 

  25. Kingsbury DJ, Bader-Meunier B, Patel G, et al. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433–41.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Horneff G, Ruperto N, Wallace C, et al. Long-term safety and effectiveness of adalimumab in children with moderately to severely active polyarticular or polyarticular-course juvenile idiopathic arthritis. Ann Rheum Dis. 2014;73 Suppl 2:61–2.

    Article  Google Scholar 

  27. Schmeling H, Minden K, Foeldvari I, et al. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German biologics JIA registry. Arthritis Rheumatol. 2014;66(9):2580–9.

    Article  CAS  PubMed  Google Scholar 

  28. Tynjälä P, Vähäsalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70(9):1605–12.

    Article  PubMed  Google Scholar 

  29. Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, et al. Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years. J Rheumatol. 2014;41(7):1409–15.

    Article  CAS  PubMed  Google Scholar 

  30. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132(3):863–73.

    Article  CAS  PubMed  Google Scholar 

  31. Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57(9):1318–30.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383–91.

    Article  CAS  PubMed  Google Scholar 

  33. Ruperto N, Lovell DJ, Quartier P. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:1792–802.

    Article  CAS  PubMed  Google Scholar 

  34. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.

    Article  CAS  PubMed  Google Scholar 

  35. Yokota S, Imagawa T, Mori M, et al. Long-term safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol. 2014;41(4):759–67.

    Article  CAS  PubMed  Google Scholar 

  36. Benedetti F, Brunner H, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95.

    Article  PubMed  Google Scholar 

  37. Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110–7. doi:10.1136/annrheumdis-2014-205351.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, Tanaka K, Minota, S. (2015) Safety and effectiveness of tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from a 1-year of postmarketing surveillance follow-up of 417 patients in Japan. In press

  39. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–406.

    Article  CAS  PubMed  Google Scholar 

  40. Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28(2):129–37.

    Article  PubMed  Google Scholar 

  41. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–8.

    Article  CAS  PubMed  Google Scholar 

  42. Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:545–55.

    Article  CAS  PubMed  Google Scholar 

  44. Beukelman T, Xie F, Chen L, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(8):2773–80.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Horneff G, Huppertz HI, Ganser G, Haas JP, Foeldvari I, Minden K. Drug safety in treatment of juvenile idiopathic arthritis (JIA): biologic therapy compared with MTX. Arthritis Rheum. 2014;66(Supplement):S121.

    Google Scholar 

  46. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737–44.

    Article  CAS  PubMed  Google Scholar 

  47. Nimmrich S, Horneff G. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients. Rheumatol Int. 2015;35(3):465–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Gerd Horneff declares the receipt of research grants from AbbVie, Pfizer, and Roche and speaker’s fees from AbbVie, Novartis, Pfizer, and Roche.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Centre for Paediatric Rheumatology, Department of Paediatrics, Asklepios Clinic Sankt Augustin, Arnold-Janssen-Str. 29, 53757, Sankt Augustin, Germany

    Gerd Horneff

Authors
  1. Gerd Horneff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerd Horneff.

Additional information

This article is part of the Topical Collection on Infections and Arthritis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horneff, G. Biologic-Associated Infections in Pediatric Rheumatology. Curr Rheumatol Rep 17, 66 (2015). https://doi.org/10.1007/s11926-015-0542-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-015-0542-z

Keywords

Search

Navigation